Výsledky vyhledávání - "Bettina Rehbein"

729 Targeting epidermal growth factor receptor (EGFR)-expressing solid tumors with AFM24, a novel CD16A bispecific innate cell engager: comprehensive correlative science findings from a phase 1 study

Autor: Gabriele Hintzen, Susanne Wingert, Michael Emig, Pilar Nava-Parada, Kerstin Pietzko, Laura Kohlhas, Uwe Reusch, Melissa Berrien-Elliott, Todd Fehniger, Mark Foster, Paolo Nuciforo, Ester Castillo Andreo, Sina Staeble, Paulien Ravenstijn, Bettina Rehbein, Erich Rajkovic, Arndt Schottelius, Joachim Koch

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4857f1d8e32d5111d555caf680b9198
https://doi.org/10.1136/jitc-2022-sitc2022.0729

Zobrazit plný text záznamu

Abstract CT149: A phase 1/2a first-in-human study of AFM24, a CD16A/epidermal growth factor (EGFR) bispecific Innate Cell Engager (ICE®), in patients with locally advanced or metastatic EGFR-expressing solid tumors: Preliminary findings from the dose-escalation phase

Autor: Anthony El-Khoueiry, Juanita Lopez, Omar Saavedra, Mark Awad, Jacob Thomas, Crescens Tiu, Elena Garralda, Bettina Rehbein, Gabriele Hintzen, Kerstin Pietzko, Christa Raab, Erich Rajkovic, Paulien Ravenstijn, Michael Emig

Publikováno v: Cancer Research. 82:CT149-CT149

AFM24 is a first-in-class, tetravalent, bispecific ICE® that binds to EGFR on tumor cells and CD16A on natural killer (NK) cells and macrophages, inducing antibody-mediated cytotoxicity and antibody-mediated phagocytosis, respectively. Preclinical i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71d302db23b3459f4bbde26f370f2b46
https://doi.org/10.1158/1538-7445.am2022-ct149

Zobrazit plný text záznamu

A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale

Autor: Omar Saavedra Santa Gadea, Elena Garralda, Juanita Suzanne Lopez, Mark M. Awad, Jacob Stephen Thomas, Crescens Diane Tiu, Daniela Morales-Espinosa, Christa Raab, Bettina Rehbein, Gabriele Hintzen, Kerstin Pietzko, Paulien Ravenstijn, Michael Emig, Anthony B. El-Khoueiry

Publikováno v: Journal of Clinical Oncology. 40:TPS2672-TPS2672

TPS2672 Background: AFM24 is a first-in-class, tetravalent, bispecific, fragment crystallizable-silenced antibody that targets epidermal growth factor receptor-expressing (EGFR+) solid tumors. Of its 4 binding sites, 2 are specific for EGFR, and 2 ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4560271e9ef9f652ce9d4e18733c9232
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2672

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání